Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Prevnar 13 in Healthy Infants in France
NCT00366678Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2006
- Primary completion
- Nov 2008
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Prevnar 13 in pneumococcal disease (2 arms), sponsored by Pfizer. Primary endpoints: Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria, Tetanus, Hib, Polio, Pertussis, Percentage of Participants Achieving a Pneumococcal Antibody Level >=0.35µg/mL (ELISA) and 3 more. Started Oct 2006; status: completed.
02
Drugs
Prevnar 13
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT00366678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00366678.